Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sonoma Pharmaceuticals (SNOA) Non-Current Assets (2016 - 2025)

Sonoma Pharmaceuticals has reported Non-Current Assets over the past 15 years, most recently at $1.5 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 14.75% year-over-year to $1.5 million; the TTM value through Dec 2025 reached $5.4 million, down 19.81%, while the annual FY2025 figure was $1.0 million, 52.33% down from the prior year.
  • Non-Current Assets for Q4 2025 was $1.5 million at Sonoma Pharmaceuticals, up from $1.4 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $2.7 million in Q4 2022 and troughed at $1.0 million in Q1 2025.
  • A 5-year average of $1.9 million and a median of $2.0 million in 2021 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: soared 63.59% in 2022 and later crashed 52.33% in 2025.
  • Year by year, Non-Current Assets stood at $1.6 million in 2021, then skyrocketed by 63.59% to $2.7 million in 2022, then fell by 21.51% to $2.1 million in 2023, then plummeted by 39.13% to $1.3 million in 2024, then rose by 14.75% to $1.5 million in 2025.
  • Business Quant data shows Non-Current Assets for SNOA at $1.5 million in Q4 2025, $1.4 million in Q3 2025, and $1.5 million in Q2 2025.